A clinical trial is a research study conducted with volunteers to evaluate the safety & effectiveness of a new medical treatment or intervention. It involves carefully designed protocols and methodology to gather scientific evidence and assess the potential benefits and risks of the intervention. These trials play a crucial role in advancing medical knowledge and improving healthcare by testing new drugs, therapies, and medical devices before they can be approved for widespread use.
MacTel is a bilateral retinal disease that leads to a gradual loss of central vision. The disease causes photoreceptors to be lost in a well-defined area (Ellipsoid Zone) of the retina. As the disease progresses, patients experience blurring, distorted vision, trouble reading, and loss of central vision. Our Encapsulated Cell Therapy (ECT) Platform releases Ciliary Neurotrophic Factor (CNTF), a protein shown to protect against the progressive loss of photoreceptors.
There are no known pharmacological treatment options for MacTel today.
United States
Australia
France
Germany
United Kingdom
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 – Protocol A
ClinicalTrials.gov ID NCT03316300, Information provided by Neurotech Pharmaceuticals (Responsible Party), Last Update Posted 2023-02-08
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
ClinicalTrials.gov ID NCT03319849, Information provided by Neurotech Pharmaceuticals (Responsible Party), Last Update Posted 2023-02-08
NTMT-03A and NTMT-03B Participant Letter
November 2022
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
ClinicalTrials.gov ID NCT04729972, Information provided by Neurotech Pharmaceuticals (Responsible Party), Last Update Posted 2023-02-08
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
ClinicalTrials.gov ID NCT03071965. Information provided by Neurotech Pharmaceuticals (Responsible Party), Last Update Posted 2022-03-17
Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.
Emily Y. Chew, MD, Traci E. Clemons, PhD, Glenn J. Jaffe, MD, Charles A. Johnson, MD, Sina Farsiu, PhD, Eleonora M. Lad, MD, PhD, Robyn Guymer, MD, PhD,
Philip Rosenfeld, MD, PhD, Jean-Pierre Hubschman, MD, Ian Constable, MD, Henry Wiley, MD, Lawrence J. Singerman, MD, Mark Gillies, MD, PhD,
Grant Comer, MD, Barbara Blodi, MD, Dean Eliott, MD, Jiong Yan, MD, Alan Bird, MD, Martin Friedlander, MD, PhD, MacTel Type 2-Ph 2 CNTF Research Group.
DOI:https://doi.org/10.1016/j.ophtha.2018.09.041
Ciliary Neurotrophic Factor Delivered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration
Kang Zhang, Jill J. Hopkins, Jeffrey S. Heier, David G. Birch, Lawrence S. Halperin, Thomas A. Albini, David M. Brown, Glenn J. Jaffe, Weng Tao, and George A. Williams.
Proc Natl Acad Sci U S A. 2011 Apr 12; 108(15): 6241–6245. Published online 2011 Mar 28. doi: 10.1073/pnas.1018987108
Ciliary Neurotrophic Factor (CNTF) for Human Retinal Degeneration: Phase I Trial of CNTF Delivered by Encapsulated Cell Intraocular Implants
Paul A. Sieving, Rafael C. Caruso, Weng Tao,§ Hanna R. Coleman, Darby J. S. Thompson, Keri R. Fullmer, and Ronald A. Bush.
Proc Natl Acad Sci U S A. 2006 Mar 7; 103(10): 3896–3901. Published online 2006 Feb 27. doi: 10.1073/pnas.0600236103
Longitudinal Study of Cone Photoreceptors During Retinal Degeneration and in Response to Ciliary Neurotrophic Factor Treatment
Katherine E Talcott, Kavitha Ratnam, Sanna M Sundquist, Anna S Lucero, Brandon J Lujan, Weng Tao, Travis C Porco, Austin Roorda, Jacque L Duncan.
PMID: 21087953 PMCID: PMC3080173 DOI: 10.1167/iovs.10-6479
Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results from a Phase 1 Safety Trial
Emily Y Chew , Traci E Clemons , Tunde Peto, Ferenc B Sallo, Avner Ingerman, Weng Tao, Lawrence Singerman, Steven D Schwartz, Neal S Peachey,
Alan C Bird, MacTel-CNTF Research Group. PMID: 25528956 PMCID: PMC4361328 DOI: 10.1016/j.ajo.2014.12.013
Ciliary Neurotrophic Factor Treatment Improves Retinal Structure and Function in Macular Telangiectasia Type 2
Jacque L Duncan, PMID: 30910039 DOI: 10.1016/j.ophtha.2018.12.023
Neurotech required conditions for consideration of Pre-Approval Access and Single Patient Requests